Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2009

View Archived Issues

Shanghai Institute Materia Medica claims PPARgamma agonists for polycystic kidney disease

Banyu presents Wee1 kinase inhibitors as oncolytic compounds

Boehringer Ingelheim discloses novel cannabinoid CB2 receptor agonists as analgesics

GlaxoSmithKline claims novel stearoyl-CoA desaturase inhibitors for the treatment of obesity

Novel orexin receptor antagonists for sleep disorders patented by Merck & Co.

10-year results show long-term effects of gene therapy for SCID-X1

AMA1-C1/Alhydrogel vaccine fails to reach primary endpoint in phase II trial in Malian children

DNAI gene therapy corrects dysfunction seen in primary ciliary dyskinesia

QLT reports positive primary analysis results from phase II RADICAL study in wet AMD

WELCOME results show effects of certolizumab pegol in Crohn's disease patients failing infliximab

Inovio Biomedical merges with VGX Pharmaceuticals

Raptor initiates dosing in phase IIb clinical trial of DR Cysteamine in nephropathic cystinosis

Clinical Data presents positive results from second phase III vilazodone trial

Snapshots: Exelixis oncolytic compounds discussed at ASCO annual meeting

Multiple clinical data presentations on carfilzomib given at ASCO

Clinical results with salirasib reported for lung, pancreatic cancer studies

PolyMedix receives DTRA grant to develop antibiotic compounds for biowarfare pathogens

Novartis and Nordic complete enrollment in phase III study of oral calcitonin in osteoarthritis

Takeda revises development strategy for alogliptin and alogliptin/pioglitazone

Wellcome Trust awards EUR 5.15 million grant to NVGH to develop typhoid vaccine

FDA places partial clinical hold on Genmab's zalutumumab

Peregrine reports positive results from three phase II clinical trials of bavituximab in cancer

German regulator clears Silence Therapeutics' CTA for phase I study of ATU-027 in cancer

FDA accepts GE Healthcare's NDA for DaTSCAN for priority review

Kamada submits BLA for intravenous AAT for alpha-1 antitrypsin deficiency

FDA denies Advaxis' request for orphan drug designation for ADXS-11-001 in invasive cervical cancer

FDA issues complete response letter to ViroPharma regarding sBLA for Cinryze in HAE

Novavax and NIH to evaluate a virus-like particle vaccine for influenza A (H1N1)

AstraZeneca and Abbott submit NDA for Certriad for mixed dyslipidemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...